SECURITIES AND EXCHANGE COMMISSION
                             Washington, D. C. 20549





                                    FORM 8-K





                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):  November 30, 2004



                                   INYX, INC.

             (Exact name of registrant as specified in its charter)



Nevada                               333-83152                   75-2870720
- ------                               ---------                   ----------
(State or other jurisdiction        (Commission              (I.R.S. Employer
    of incorporation)               File Number)             Identification No.)



                825 Third Avenue, 40th Floor, New York, NY 10022
                ------------------------------------------------
               (Address of principal executive offices) (Zip Code)
       Registrant's telephone number, including area code: (212) 838-1111

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]      Written  communications  pursuant to Rule 425 under the  Securities Act
         (17 CFR 230.425)

[_]      Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
         CFR 240.14a-12)

[_]      Pre-commencement  communications  pursuant to Rule  14d-2(b)  under the
         Exchange Act (17 CFR 240.14d-2(b))

[_]      Pre-commencement  communications  pursuant to Rule  13e-4(c)  under the
         Exchange Act (17 CFR 240.13e-4(c))





Item 1.01.    Entry into a Material Definitive Agreement

         On November 30,  2004,  Registrant  signed an Amendment to  Development
Agreement   with  Stiefel   Laboratories,   Inc.  Such  amendment  adds  another
proprietary  pharmaceutical  product  to the  arrangement  by  which  Registrant
manufactures  pharmaceutical  products for Stiefel.  The Amendment  augments the
original Development Agreement filed in a Form 8-K dated March 15, 2004.

Item 9.01.    Financial Exhibits, Pro Forma Financial Information and Exhibits.

         *10.13.6 Amendment to Development Agreement

         --------------------------
         *Confidentiality has been requested with respect to certain portions of
         this Agreement.

                                   SIGNATURES

         Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                       INYX, INC.



                                                       By: /s/ Jack Kachkar
                                                          ----------------------
                                                          Jack Kachkar, Chairman

Dated:            November 30, 2004